- The DSMB has recommended that the VIR-7831 arm of the trial be closed to enrollment while the data mature. The recommendation was based on pre-planned safety & efficacy data review of the first 300 patients hospitalized with COVID-19 enrolled in ACTIV-3
- The companies will continue discussions with the NIH to further assess the potential of VIR-7831 in the hospitalized population as all parties gain a fuller understanding of the still-emerging data.
- VIR-7831 is an investigational, dual-action mAb that blocks viral entry into healthy cells and clear infected cells, which may protect patients from disease progression
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Sathguru